Celularity Inc., (CELU): Price and Financial Metrics
CELU Price/Volume Stats
| Current price | $3.21 | 52-week high | $8.90 |
| Prev. close | $3.06 | 52-week low | $1.59 |
| Day low | $3.04 | Volume | 20,100 |
| Day high | $3.36 | Avg. volume | 224,518 |
| 50-day MA | $4.68 | Dividend yield | N/A |
| 200-day MA | $3.34 | Market Cap | 62.20M |
CELU Stock Price Chart Interactive Chart >
Celularity Inc., (CELU) Company Bio
Celularity Inc., a clinical stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies. The company is developing unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR, and mesenchymal-like adherent stromal cells targeting indications across cancer, infectious diseases, and degenerative diseases. It also develops and manufactures biomaterials derived from the postpartum placenta. The company was founded in 2016 and is based in Florham Park, New Jersey.
Latest CELU News From Around the Web
Below are the latest news stories about CELULARITY INC that investors may wish to consider to help them evaluate CELU as an investment opportunity.
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q FilingFLORHAM PARK, N.J., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a biotechnology company developing allogeneic cell therapies and biomaterial products, announced today that on November 21, 2023, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with Nasdaq’s continued listing requirements of the Company’s failure to timely file a Form 10-Q for th |
Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product ClassificationSFDA Classification Establishes Clear Regulatory Pathway for Importation of Celularity’s Commercial Biomaterial Products into the Kingdom of Saudi Arabia FLORHAM PARK, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies and advanced biomaterial products, today announced that its Halal Certified biomaterial products have been classified by the Saudi Food and Drug Authority |
Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of DirectorsPharmaceutical and Academic Veteran Brings Significant Innovative Technology and Development Expertise Launching New Cellular TherapiesFLORHAM PARK, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies and advanced biomaterial products, today announced the appointment of Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors. Dr. Ling, a distinguished academic and |
Celularity Announces Multi-Year Research Collaboration Services Agreement With RegeneronCelularity to provide research support for Regeneron's targeted, allogeneic, chimeric antigen receptor (CAR) T-cell therapyAgreement underscores Celularity's demonstrated expertise in cell therapy research FLORHAM PARK, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing allogeneic cell therapies and biomaterial products, announced today a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals, Inc. |
Celularity Inc. Announces $3 Million Registered Direct OfferingFLORHAM PARK, N.J., July 27, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has entered into a definitive agreement with a single, healthcare-focused institutional investor for the purchase and sale of 8,571,428 shares of its Class A common stock together with warrants to purchase up to 8,571,428 shares of its Class A common stock at a combined |
CELU Price Returns
| 1-mo | -39.09% |
| 3-mo | -7.76% |
| 6-mo | 53.59% |
| 1-year | -47.82% |
| 3-year | -96.82% |
| 5-year | N/A |
| YTD | 29.75% |
| 2023 | -80.82% |
| 2022 | -74.80% |
| 2021 | -53.45% |
| 2020 | 10.55% |
| 2019 | N/A |
Loading social stream, please wait...